Compare KRYS & NEU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | NEU |
|---|---|---|
| Founded | 2015 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.6B |
| IPO Year | 2017 | 2004 |
| Metric | KRYS | NEU |
|---|---|---|
| Price | $327.51 | $917.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $392.11 | N/A |
| AVG Volume (30 Days) | ★ 204.3K | 87.1K |
| Earning Date | 11-02-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 1.34% |
| EPS Growth | ★ 128.00 | N/A |
| EPS | 3.62 | ★ 27.14 |
| Revenue | $389,130,000.00 | ★ $2,725,169,000.00 |
| Revenue This Year | $31.33 | N/A |
| Revenue Next Year | $27.55 | N/A |
| P/E Ratio | $93.08 | ★ $33.35 |
| Revenue Growth | ★ 33.94 | N/A |
| 52 Week Low | $179.16 | $580.03 |
| 52 Week High | $382.54 | $981.66 |
| Indicator | KRYS | NEU |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 52.90 |
| Support Level | $331.79 | $833.43 |
| Resistance Level | $371.16 | $915.07 |
| Average True Range (ATR) | 9.85 | 20.32 |
| MACD | -1.37 | 0.63 |
| Stochastic Oscillator | 17.44 | 63.06 |
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
NewMarket Corp is a holding company that, through its subsidiaries, manufactures and sells petroleum additives used in lubricating oils and fuels to enhance performance. The company operates through two segments: petroleum additives, mainly represented by Afton, where lubricant additives improve the efficiency and durability of base fluids and fuel additives help meet fuel specifications and improve fuel performance, and specialty materials, represented by AMPAC and Calca, including the antiknock compounds business of Ethyl, where primary raw materials include electricity, sodium chlorate, ammonia, chlorine, caustic, and hydrochloric acid, with graphite used in electrolytic cells. The company has operations in North America, Latin America, Asia Pacific, and EMEAI regions.